The Eye As a Biomarker for Alzheimer's Disease

Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in dementia and eventual death. It is the leading cause of dementia and the number of cases are projected to rise in the next few decades. Pathological hallmarks of AD include the presence of hyperphosphorylated tau...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in neuroscience Vol. 10; p. 536
Main Authors: Lim, Jeremiah K H, Li, Qiao-Xin, He, Zheng, Vingrys, Algis J, Wong, Vickie H Y, Currier, Nicolas, Mullen, Jamie, Bui, Bang V, Nguyen, Christine T O
Format: Journal Article
Language:English
Published: Switzerland Frontiers Research Foundation 17-11-2016
Frontiers Media S.A
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer's disease (AD) is a progressive neurodegenerative disorder resulting in dementia and eventual death. It is the leading cause of dementia and the number of cases are projected to rise in the next few decades. Pathological hallmarks of AD include the presence of hyperphosphorylated tau and amyloid protein deposition. Currently, these pathological biomarkers are detected either through cerebrospinal fluid analysis, brain imaging or post-mortem. Though effective, these methods are not widely available due to issues such as the difficulty in acquiring samples, lack of infrastructure or high cost. Given that the eye possesses clear optics and shares many neural and vascular similarities to the brain, it offers a direct window to cerebral pathology. These unique characteristics lend itself to being a relatively inexpensive biomarker for AD which carries the potential for wide implementation. The development of ocular biomarkers can have far implications in the discovery of treatments which can improve the quality of lives of patients. In this review, we consider the current evidence for ocular biomarkers in AD and explore potential future avenues of research in this area.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Efthimios M. C. Skoulakis, Biomedical Sciences Research Centre “Alexander Fleming,” Greece; Sandra Tenreiro, CEDOC-Chronic Diseases Research Center, Portugal
Edited by: Raymond Chuen-Chung Chang, University of Hong Kong, Hong Kong
This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
ISSN:1662-4548
1662-453X
1662-453X
DOI:10.3389/fnins.2016.00536